Tocilizumab as a Therapeutic Agent for Critically Ill Patients Infected with SARS‐CoV‐2

• Main Authors: Russell M. Petrak (Author), Nathan C. Skorodin (Author), Nicholas W. Van Hise (Author), Robert M. Fliegelman (Author), Jonathan Pinsky (Author), Vishal Didwania (Author), Michael Anderson (Author), Melina Diaz (Author), Kairav Shah (Author), Vishnu V. Chundi (Author), David W. Hines (Author), Brian P. Harting (Author), Kamo Sidwha (Author), Brian Yu (Author), Paul Brune (Author), Anjum Owaisi (Author), David Beezhold (Author), Joseph Kent (Author), Dana Vais (Author), Alice Han (Author), Neethi Gowda (Author), Nishi Sahgal (Author), Jan Silverman (Author), Jonathan Stake (Author), Jenie Nepomuceno (Author), Renuka Heddurshetti (Author)
• 格式: 圖書
• 出版: Wiley, 2021-11-01T00:00:00Z.
• 主題: article
• 在線閱讀: Connect to this object online.

Tocilizumab is an IL‐6 receptor antagonist with the ability to suppress the cytokine storm in critically ill patients infected with severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2). We evaluated patients treated with tocilizumab for a SARS‐CoV‐2 infection who were admitted between March...